Andrew Walkty

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8560219/publications.pdf Version: 2024-02-01



ΔΝΠΩΕΊΝ ΜΛΙΚΤΥ

#	Article	IF	CITATIONS
1	Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Drugs, 2018, 78, 65-98.	4.9	291
2	Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs, 2016, 76, 567-588.	4.9	199
3	Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Review of Anti-Infective Therapy, 2012, 10, 459-473.	2.0	171
4	Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evidence, 2014, 9, 13.	4.7	142
5	42936 pathogens from Canadian hospitals: 10 years of results (2007–16) from the CANWARD surveillance study. Journal of Antimicrobial Chemotherapy, 2019, 74, iv5-iv21.	1.3	43
6	Antimicrobial susceptibility of 2906 Pseudomonas aeruginosa clinical isolates obtained from patients in Canadian hospitals over a period of 8 years: Results of the Canadian Ward surveillance study (CANWARD), 2008–2015. Diagnostic Microbiology and Infectious Disease, 2017, 87, 60-63.	0.8	36
7	Dramatic rise in the proportion of ESBL-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates identified in Canadian hospital laboratories from 2007 to 2016. Journal of Antimicrobial Chemotherapy, 2019, 74, iv64-iv71.	1.3	36
8	In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units. Diagnostic Microbiology and Infectious Disease, 2020, 97, 115012.	0.8	36
9	Frequency of MCR-1-mediated colistin resistance among Escherichia coli clinical isolates obtained from patients in Canadian hospitals (CANWARD 2008-2015). CMAJ Open, 2016, 4, E641-E645.	1.1	24
10	Empyema Caused by <i>Clostridium bifermentans</i> : A Case Report. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 105-107.	0.7	23
11	<i>Cardiobacterium hominis</i> Endocarditis: A Case Report and Review of the Literature. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005, 16, 293-297.	0.7	22
12	In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008–16. Journal of Antimicrobial Chemotherapy, 2018, 73, 703-708.	1.3	21
13	Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs, 2021, 81, 233-256.	4.9	20
14	Isolation of multiple carbapenemase-producing Gram-negative bacilli from a patient recently hospitalized in Nigeria. Diagnostic Microbiology and Infectious Disease, 2015, 81, 296-298.	0.8	19
15	<i>In Vitro</i> Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	19
16	Lemierre's Syndrome. New England Journal of Medicine, 2019, 380, e16.	13.9	17
17	Real-life experience with ceftobiprole in Canada: Results from the CLEAR (CanadianLEadership) Tj ETQq1 1 0.78	4314 rgBT 0.9	/Overlock 10

18Jamestown Canyon virus meningoencephalitis mimicking migraine with aura in a resident of Manitoba.
Cmaj, 2018, 190, E262-E264.0.916

#	Article	IF	CITATIONS
19	Disseminated <i>Mycobacterium bovis</i> infection postâ€kidney transplant following remote intravesical <scp>BCG</scp> therapy for bladder cancer. Transplant Infectious Disease, 2018, 20, e12931.	0.7	15
20	Central nervous system blastomycosis diagnosed using the MVista® Blastomyces quantitative antigen enzyme immunoassay test on cerebrospinal fluid: A case report and review of the literature. Diagnostic Microbiology and Infectious Disease, 2018, 90, 102-104.	0.8	12
21	Anaplasmosis: An emerging tick-borne disease of importance in Canada. IDCases, 2018, 14, e00472.	0.4	12
22	Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs, 2022, 82, 533-557.	4.9	12
23	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against 338 Molecularly Characterized Gentamicin-Nonsusceptible Gram-Negative Clinical Isolates Obtained from Patients in Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2015, 59, 3623-3626.	1.4	10
24	Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007–19. JAC-Antimicrobial Resistance, 2022, 4, dlab197.	0.9	10
25	Osteomyelitis Due to Multiple Carbapenemase-Producing Gram-Negative Bacteria: The First Case Report of a GES-13-ProducingPseudomonas aeruginosalsolate in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 229-231.	0.7	9
26	Identification and Characterization of a Novel FosA7 Member from Fosfomycin-Resistant Escherichia coli Clinical Isolates from Canadian Hospitals. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	9
27	An Unusual Case ofStreptococcus anginosusGroup Pyomyositis Diagnosed Using Direct 16S Ribosomal DNA Sequencing. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 32-34.	0.7	8
28	ESBL-positive <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from across Canada: CANWARD surveillance study, 2007–18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2815-2824.	1.3	8
29	In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagnostic Microbiology and Infectious Disease, 2021, 101, 115418.	0.8	8
30	Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian) Tj ETQq0 0 0 rgE 25, 346-350.	BT /Overloo 0.9	k 10 Tf 50 3 7
31	Use of Fosfomycin Etest To Determine <i>In Vitro</i> Susceptibility of Clinical Isolates of <i>Enterobacterales</i> Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci. Journal of Clinical Microbiology, 2021, 59, e0163521.	1.8	7
32	Evaluation of MRSA <i>Select</i> ^{â,,¢} Chromogenic Medium for the Early Detection of Methicillin-Resistant <i>Staphylococcus aureus</i> from Blood Cultures. Canadian Journal of Infectious Diseases and Medical Microbiology, 2013, 24, e113-e116.	0.7	6
33	Marked peripheral eosinophilia due to prolonged administration of posaconazole. JMM Case Reports, 2017, 4, e005100.	1.3	6
34	Case Report: A Case of Colorado Tick Fever Acquired in Southwestern Saskatchewan. American Journal of Tropical Medicine and Hygiene, 2018, 98, 891-893.	0.6	6
35	An 81-year-old Male With a Pulsatile Abdominal Mass. Clinical Infectious Diseases, 2019, 69, 1456-1459.	2.9	5
36	Keeping an open mind about meningitis: a case report of carcinomatous meningitis. Canadian Journal of Emergency Medicine, 2011, 13, 352-356.	0.5	4

#	Article	IF	CITATIONS
37	Frequency of 16S ribosomal RNA methyltransferase detection among Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from patients in Canadian hospitals (CANWARD, 2013–2017). Diagnostic Microbiology and Infectious Disease, 2019, 94, 199-201.	0.8	4
38	Report of a KPC-producing Pseudomonas aeruginosa isolate in Canada. Journal of Antimicrobial Chemotherapy, 2019, 74, 1748-1749.	1.3	4
39	Comparison of phenotypic antimicrobial susceptibility testing results and WGS-derived genotypic resistance profiles for a cohort of ESBL-producing <i>Escherichia coli</i> collected from Canadian hospitals: CANWARD 2007–18. Journal of Antimicrobial Chemotherapy, 2021, 76, 2825-2832.	1.3	4
40	Minocycline-induced cutaneous hyperpigmentation. Cmaj, 2020, 192, E981-E981.	0.9	3
41	Emergence of Morganellaceae Harboring bla IMP-27 Metalloenzyme in Canada. MSphere, 2021, 6, .	1.3	3
42	Failure of a multiplex polymerase chain reaction assay to detect IMP-27 in a clinical isolate of Morganella morganii. Diagnostic Microbiology and Infectious Disease, 2018, 92, 194-195.	0.8	2
43	Fosfomycin resistance mediated by fos genes remains rare among extended-spectrum beta-lactamase-producing Escherichia coli clinical isolates recovered from the urine of patients evaluated at Canadian hospitals (CANWARD, 2007–2017). Diagnostic Microbiology and Infectious Disease, 2020, 96, 114962.	0.8	2
44	Tinea barbae presenting as a kerion. Postgraduate Medical Journal, 2020, 96, 441-441.	0.9	2
45	A 49-Year-Old Male With Fever and Abdominal Pain. Clinical Infectious Diseases, 2021, 73, 2140-2143.	2.9	2
46	Effect of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study. BMC Gastroenterology, 2022, 22, 140.	0.8	2
47	Time trends and predictors of laboratory-confirmed recurrent and severe <i>Clostridioides difficile</i> infections in Manitoba: a population-based study. CMAJ Open, 2020, 8, E737-E746.	1.1	1
48	An 82-Year-Old Male With a Liver Abscess. Open Forum Infectious Diseases, 2020, 7, ofaa336.	0.4	1
49	Cefotaxime susceptibility should not be used to predict ceftriaxone susceptibility among Klebsiella oxytoca clinical isolates. Journal of Global Antimicrobial Resistance, 2020, 21, 270-271.	0.9	1
50	Condyloma lata. IDCases, 2021, 26, e01321.	0.4	1
51	254In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013. Open Forum Infectious Diseases, 2014, 1, S109-S109.	0.4	0
52	In Vitro Activity of Newer Antimicrobials and Relevant Comparators Vs. 349 Stenotrophomonas maltophilia Clinical Isolates Obtained from Patients in Canadian Hospitals (CANWARD, 2011–2016). Open Forum Infectious Diseases, 2017, 4, S367-S368.	0.4	0
53	In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016. Open Forum Infectious Diseases, 2017, 4, S372-S372.	0.4	0
54	2383. <i>In Vitro</i> Activity of Ceftolozane–Tazobactam in Comparison With Ceftazidime–Avibactam vs. Antimicrobial Non-Susceptible <i>Pseudomonas aeruginosa</i> Clinical Isolates, Including Multidrug-Resistant and Extensively Drug-Resistant Subsets: CANWARD, 2007–2017. Open Forum Infectious Diseases, 2018, 5, S710-S710.	0.4	0

ANDREW WALKTY

#	Article	IF	CITATIONS
55	Answer to November 2019 Photo Quiz. Journal of Clinical Microbiology, 2019, 57, .	1.8	Ο
56	In vitro susceptibility of common bacterial pathogens causing respiratory tract infections in Canada to lefamulin, a new pleuromutilin. Jammi, 2021, 6, 149-162.	0.3	0
57	Photo Quiz: A 59-Year-Old Male with Nodular Cutaneous Lesions. Journal of Clinical Microbiology, 2019, 57, .	1.8	Ο
58	Pulmonary empyema in a patient with schizophrenia and poor dentition. Cmaj, 2021, 193, E1695-E1695.	0.9	0
59	Ignatzschineria indica bloodstream infection associated with maggot infestation of a wound in a patient from Canada. Jammi, 2020, 5, 193-200.	0.3	Ο
60	Atypical presentation of a methicillin-resistant Staphylococcus aureus brain abscess. IDCases, 2021, 26, e01335.	0.4	0